A close-up view highlights the skill and control required to create clean, accurate road markings.

A simple birthday idea quickly turns into something wildly ambitious as invitations are sent far beyond what seems realistic, ...

Share on Pinterest Could a new oral option help to meet the growing demand for GLP-1 medications? Image Credit: Medical News Today/Photo by Eli Lilly The Food and Drug Administration (FDA) has ...

23andMe Research Institute, a nonprofit medical research organization, announced the publication of a study that identifies genetic predictors for GLP-1 weight loss efficacy and side effects. GLP-1 ...

The GLP-1 weight loss drugs revolutionizing the treatment of obesity, diabetes and a slew of other diseases come with a major caveat: They don’t work for everyone. Some people experience profound ...

Of all the millions of people who have tried weight-loss drugs such as Wegovy and Zepbound, nearly one in four people don’t respond to treatment. They lose little weight, or none at all, and see few ...

Employer cost coverage increases likelihood of GLP-1 use (65% overall), peaking in ages 35–44 (75%) and declining sharply among workers ≥65 (37%). Behavioral support programs shift willingness to self ...

Matthew Herper covers medical innovation — both its promise and its perils. Specific changes in two genes appear to help predict whether patients will lose substantial weight on GLP-1 drugs used to ...

Ruth J. F. Loos is in the Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen 2200, Denmark. Read the paper: ...

23andMe Research Institute, a nonprofit medical research organization, announced the publication of a study that identifies genetic predictors for GLP-1 weight loss efficacy and side effects. GLP-1 ...

NEW YORK — Morgan Stanley Research is now projecting GLP-1 usage among US consumers will reach approximately 55 million by 2035. A previous projection by the market trends analyst saw GLP-1 usage ...